Treatment of Netherton syndrome with upadacitinib

Abstract

We reported the case of a patient with Netherton syndrome (NS) who showed remarkable cutaneous improvement using upadacitinib in the short term, but the efficacy decreased long term. This patient’s case demonstrates that Janus kinase inhibitors have reduced long-term clinical efficacy, which is the same as other biologic therapies used to treat patients with NS. This shows that NS is a complex skin disorder and more studies and clinical trials are required focusing on the long-term efficacy of these drugs.

Topics & Concepts